Multiple myeloma is a rare but serious type of blood cancer that develops in plasma cells, a type of white blood cell found in the bone marrow. Plasma cells play an important role in your immune system by producing antibodies that help protect your body from infections. When these cells become cancerous, they multiply uncontrollably, crowding out healthy blood cells and affecting multiple organs throughout the body.
Although multiple myeloma is not among the most common cancers, it accounts for approximately 10% of all blood cancers worldwide. Advances in diagnosis, targeted therapies, and supportive care have significantly improved treatment outcomes, allowing many patients to live longer and maintain a better quality of life.
If you or someone you know has recently been diagnosed with multiple myeloma, understanding the disease is the first step toward making informed healthcare decisions. In this guide, we’ll explain what multiple myeloma is, its symptoms, possible causes, risk factors, and why early diagnosis matters.
Multiple myeloma is a cancer of plasma cells, which are produced inside the bone marrow. Under normal conditions, plasma cells create antibodies that help the body fight bacteria and viruses.
In multiple myeloma, abnormal plasma cells multiply rapidly and produce defective antibodies known as M proteins (monoclonal proteins). These abnormal proteins do not protect the body against infection and can build up in the blood and urine, causing complications.
As cancerous plasma cells continue to grow, they crowd out healthy blood-forming cells inside the bone marrow. This may lead to:
Because multiple myeloma can affect several parts of the body, it is considered a systemic disease rather than a cancer limited to one organ.
Multiple myeloma primarily affects the bone marrow but can also impact the kidneys, immune system, bones, and blood.
Some of the most common complications include:
Cancerous plasma cells stimulate the breakdown of bone tissue faster than the body can rebuild it. This may result in:
The spine, ribs, pelvis, and skull are among the most commonly affected bones.
Healthy bone marrow produces red blood cells that carry oxygen throughout the body. When myeloma cells crowd the bone marrow, red blood cell production decreases, causing anemia.
Common symptoms include:
Since abnormal plasma cells do not produce effective antibodies, the immune system becomes weaker. People with multiple myeloma may experience recurrent bacterial or viral infections that require prompt medical attention.
The abnormal proteins produced by myeloma cells can accumulate in the kidneys and interfere with their ability to filter waste products from the blood. Kidney impairment is a common complication and may require close monitoring during treatment.
The symptoms of multiple myeloma can vary depending on how advanced the disease is. Some people experience only mild symptoms at first, while others develop more noticeable complications.
The most common symptoms include:
Bone pain is often one of the earliest signs of multiple myeloma. It commonly affects the:
Pain may become worse during movement or physical activity.
Many patients feel unusually tired even after getting enough sleep. This is often caused by anemia resulting from reduced red blood cell production.
A weakened immune system makes it harder for the body to fight infections.
Common infections include:
Some people lose weight without changing their diet or activity level. Unintentional weight loss should always be discussed with a healthcare professional.
Reduced oxygen delivery due to anemia may cause general weakness and difficulty performing daily activities.
Bone damage in the spine may compress nearby nerves, leading to numbness, tingling, or weakness in the arms or legs.
Because platelet production may decrease, some people notice:
The exact cause of multiple myeloma remains unknown. Researchers believe it develops through a combination of genetic changes and environmental factors.
Normally, plasma cells grow, divide, and die in a controlled manner. In multiple myeloma, certain genetic mutations cause these cells to multiply uncontrollably and survive longer than they should.
Scientists continue to study why these mutations occur, but there is currently no known way to prevent the disease completely.
Several factors may increase the likelihood of developing multiple myeloma. Having one or more risk factors does not necessarily mean someone will develop the disease, but awareness can help support earlier diagnosis.
Most cases are diagnosed in adults over the age of 60. The risk generally increases as people get older.
People with a close family member who has multiple myeloma may have a slightly higher risk than the general population.
Some patients develop multiple myeloma after a condition known as Monoclonal Gammopathy of Undetermined Significance (MGUS), which requires regular medical monitoring.
Some studies have explored possible links between long-term exposure to certain chemicals, pesticides, or radiation and an increased risk of blood cancers. However, these associations are still being researched and do not establish direct causation.
Individuals with certain immune disorders or those receiving treatments that affect the immune system may have a higher risk of developing plasma cell disorders.
Many of the symptoms of multiple myeloma such as fatigue, back pain, or recurrent infections can also be caused by less serious conditions. However, if these symptoms are persistent, worsening, or occur together, it’s important to seek medical evaluation.
A healthcare provider may recommend blood tests, urine tests, imaging studies, or other investigations to determine the underlying cause.
Early diagnosis can help guide treatment decisions and may improve long-term outcomes.
Diagnosing multiple myeloma usually begins with a review of your symptoms, medical history, and a physical examination. If multiple myeloma is suspected, your doctor may recommend several tests to confirm the diagnosis and assess how much the disease has progressed.
Blood tests are often the first step in identifying abnormalities associated with multiple myeloma.
These tests may help evaluate:
Doctors also perform specialized blood tests to detect monoclonal proteins (M proteins) produced by abnormal plasma cells.
These include:
These tests help identify the abnormal proteins commonly associated with multiple myeloma.
Some patients release abnormal proteins called Bence Jones proteins into their urine.
A urine test may include:
These tests help determine whether the kidneys are being affected by the disease.
A bone marrow biopsy is one of the most important tests for confirming multiple myeloma.
During this procedure, a doctor removes a small sample of bone marrow, usually from the hip bone, using a specialized needle.
The sample is examined under a microscope to determine:
These findings help confirm the diagnosis and may influence treatment decisions.
Because multiple myeloma frequently affects bones, imaging studies help identify bone damage before serious complications occur.
Your doctor may recommend:
Traditional skeletal surveys can identify areas where bone has become weak or damaged.
A CT scan provides more detailed images of bones and can detect small lesions not always visible on standard X-rays.
MRI is particularly useful when evaluating:
PET-CT combines metabolic and structural imaging, helping doctors identify active disease throughout the body and monitor treatment response.
Many healthcare professionals use the CRAB acronym to remember the major complications associated with active multiple myeloma.
C – High Calcium Levels
Excessive bone breakdown releases calcium into the bloodstream.
Symptoms may include:
Abnormal proteins produced by myeloma cells can damage the kidneys.
Possible symptoms include:
Reduced production of healthy red blood cells can cause:
Bone damage remains one of the most common complications.
Patients may experience:
After confirming the diagnosis, doctors determine the stage of the disease.
Staging helps estimate:
The most widely used system is the Revised International Staging System (R-ISS).
Stage I represents the earliest stage.
Patients generally have:
Many people respond well to treatment at this stage.
Stage II represents an intermediate stage.
Patients may have:
Treatment remains effective for many individuals, although closer monitoring is often required.
Stage III indicates more advanced disease.
Patients often have:
Although Stage III is more advanced, modern therapies have significantly improved treatment outcomes.
Without appropriate management, multiple myeloma can lead to several complications.
Weak bones increase the risk of fractures, even after minor injuries.
Kidney impairment may occur due to abnormal protein accumulation and high calcium levels.
Maintaining adequate hydration and following medical advice may help support kidney health during treatment.
Reduced immune function makes patients more vulnerable to infections.
Doctors may recommend preventive measures such as vaccinations and infection monitoring.
Some treatment plans may increase the risk of blood clots.
Healthcare providers assess each patient’s individual risk and may recommend preventive strategies when appropriate.
When weakened vertebrae collapse, pressure may be placed on the spinal cord.
Symptoms include:
This is considered a medical emergency and requires immediate attention.
Several types of treatment may be used alone or in combination.
Immunomodulatory drugs help strengthen the immune system while also slowing the growth of myeloma cells.
Common medicines include:
These medicines play a central role in the treatment of many patients with multiple myeloma.
Proteasome inhibitors interfere with the way myeloma cells process proteins, leading to cancer cell death.
Examples include:
These medicines are frequently combined with immunomodulatory drugs and corticosteroids.
Monoclonal antibodies are designed to recognize specific proteins on cancer cells and help the immune system destroy them.
Examples include:
These therapies have expanded treatment options, particularly for patients with relapsed or difficult-to-treat disease.
Medicines such as dexamethasone are commonly included in treatment regimens because they:
Although targeted therapies are now widely used, chemotherapy may still be recommended in certain situations, particularly before stem cell transplantation or when rapid disease control is needed.
Radiation therapy may be used to:
It is generally used for specific areas rather than as treatment for the entire disease.
Lenalidomide is one of the most commonly prescribed medicines for multiple myeloma and has become an important part of many treatment plans.
It belongs to a group of medicines called immunomodulatory drugs (IMiDs).
Rather than working in just one way, Lenalidomide has multiple actions that help control the disease.
It may:
Doctors often prescribe Lenalidomide together with other medicines rather than using it alone.
Like all prescription medicines, Lenalidomide can cause side effects, although not everyone experiences them.
Some commonly reported side effects include:
Some patients may also have an increased risk of blood clots, especially when Lenalidomide is used with certain other medicines. Your healthcare provider may recommend preventive measures based on your individual risk.
If you notice unusual bleeding, fever, severe rash, shortness of breath, or swelling of the legs, seek medical attention promptly.
Never stop or change your medication without consulting your healthcare team.
Depending on your individual treatment plan, Lenalidomide may be recommended:
The treatment schedule and dosage vary from one patient to another and should always be determined by a qualified healthcare professional.
Managing multiple myeloma involves more than treating cancer cells. Supportive care helps reduce symptoms and prevent complications.
Supportive care may include:
Doctors may recommend medications that help strengthen bones and reduce the risk of fractures.
Patients are also encouraged to:
Since multiple myeloma and its treatments can weaken the immune system, infection prevention is especially important.
Simple steps include:
Protecting kidney function is an important part of long-term care.
Healthcare providers may recommend:
A balanced diet supports overall health during treatment.
Patients are encouraged to:
Regular physical activity, when appropriate, may help:
Exercise plans should always be tailored to each individual’s condition.
Living with multiple myeloma often involves ongoing treatment and regular follow-up appointments.
Many patients continue to work, spend time with family, and enjoy daily activities while managing their condition.
Helpful strategies include:
Advances in treatment continue to improve long-term outcomes, giving many people the opportunity to live active and fulfilling lives.
Multiple myeloma is often described as a chronic condition with periods of remission and relapse.
Even after successful treatment, regular monitoring is important because the disease may return over time.
Doctors typically perform routine blood tests, imaging, and other evaluations to monitor disease activity and determine whether additional treatment is needed.
Research into multiple myeloma continues to evolve rapidly. New targeted therapies, immunotherapies, and combination treatments are expanding options for patients around the world. Participation in clinical trials may also be considered for some individuals, depending on their circumstances and the advice of their healthcare team.
At present, there is no proven way to prevent multiple myeloma because the exact cause remains unknown. Most people diagnosed with the disease have no clear or preventable risk factor.
However, maintaining good overall health may support your well-being and make it easier to manage treatment if you are diagnosed. Healthy habits include:
These measures cannot prevent multiple myeloma but contribute to better overall health.
Lenalidomide is one of the medicines that may be prescribed by specialists as part of a comprehensive treatment plan for eligible patients with multiple myeloma.
If your healthcare provider recommends Lenalidomide, it is important to:
Patients seeking information about Lenalidomide, including product details, available strengths, and general medicine information, can explore the educational resources available through LetsMeds.
Multiple myeloma is a type of blood cancer that develops in plasma cells found in the bone marrow. These abnormal cells multiply uncontrollably and can affect bones, kidneys, blood cell production, and the immune system.
While multiple myeloma is generally considered a chronic condition, significant advances in treatment have enabled many patients to achieve long periods of remission and improved quality of life. Your healthcare provider can discuss the treatment goals that are appropriate for your situation.
Early symptoms may include:
Because these symptoms can occur in many other conditions, medical evaluation is essential for an accurate diagnosis.
Doctors use a combination of blood tests, urine tests, bone marrow biopsy, and imaging studies such as CT, MRI, PET-CT, or X-rays to diagnose multiple myeloma and assess the extent of the disease.
Treatment options may include:
The choice of treatment depends on individual patient factors.
Lenalidomide is an immunomodulatory medicine that helps the immune system recognize and respond to abnormal plasma cells. It is commonly used in combination with other medicines as part of a treatment plan prescribed by a specialist.
Many people continue to work, spend time with family, and enjoy everyday activities while receiving treatment. Advances in therapy have improved disease control and quality of life, although regular medical follow-up remains important.
Most cases are not inherited. Although having a close family member with multiple myeloma may slightly increase risk, the majority of patients have no family history of the disease.
Contact your healthcare provider promptly if you experience:
These symptoms may require urgent medical attention.
Patients in the Philippines have access to multiple myeloma treatment through government hospitals, private hospitals, cancer centers, and specialist hematology or oncology clinics.
Multiple myeloma is a complex condition, but advances in medical research have greatly expanded the range of available treatments. Understanding the disease, recognizing early symptoms, and seeking timely medical care can help patients receive appropriate treatment and supportive care.
Medicines such as Lenalidomide have become an important part of treatment for many patients with multiple myeloma, often as part of combination therapy prescribed by specialists. However, treatment plans vary from person to person, making ongoing communication with your healthcare team essential.
Whether you are newly diagnosed, supporting a loved one, or looking to learn more about multiple myeloma, reliable information can help you make informed decisions throughout the treatment journey.
If you would like to learn more about Lenalidomide, its available strengths, and other specialty medicines, explore the educational resources available on LetsMeds and consult your healthcare provider for personalized medical advice.
Home Vigora 100 mg for Erectile Dysfunction: How Sildenafil Works, Uses, Benefits & Safety Guide…
Home Augmentin 625 Tablet: Uses, Dosage, Side Effects, Price & Complete Patient Guide Augmentin 625…
Home Abiraterone vs Enzalutamide: The Complete Guide to Prostate Cancer Treatment, Costs & Side Effects…
In a move that will give monetary help to disease patients across India, the 54th…
Enzalutamide: A Breakthrough Treatment for Advanced Prostate CancerEnzalutamide is a highly effective hormone therapy that…
Cancer is a disease that affects millions of people worldwide. It occurs when abnormal cells…